1)LAVAL, QC -- Jan. 8, 1999 -- Glaxo Wellcome's Heptodin (lamivudine) has been approved in China for the oral antiviral treatment of chronic hepatitis B.
Heptodin is one of the first Western medicines to be granted a Class 1 drug certificate in China, which offers the advantage of manufacturing exclusivity for the product in the treatment of hepatitis B for a period of eight years.
2) LAVAL, QC -- May 26, 1999 -- Glaxo Wellcome's (and BCHE) Zeffix (lamivudine), the world's first oral antiviral treatment of chronic hepatitis B, is approved in South Korea.
3)April 10,1997
These results indicate that over a one year period, improvements in liver histology were demonstrated in a significantly higher percentage of lamivudine patients compared to placebo (67% of patients receiving
lamivudine 100 mg orally once daily and 59% of patients receiving lamivudine 25 mg orally once daily, compared to 30% of patients receiving placebo). In addition, fewer lamivudine patients (7% of patients on 100 mg and 10% of patients on 25 mg) had deterioration of liver histology compared to placebo (32%)......
.....The presence of hepatitis B e antigen (HBeAg) in patients with hepatitis B is associated with active viral replication. The study results indicate that 16% of patients on lamivudine 100 mg compared to 4% of patients on placebo converted from being HBeAg positive to HBeAg negative with undetectable hepatitis B virus (HBV) DNA. This response, known as seroconversion, is indicative of the body's immune system mounting an effective response to this viral protein......
pslgroup.com
Jim |
